TITLE

Fund proposed to pay for drugs with greater global impact

AUTHOR(S)
Vogel, Lauren
PUB. DATE
March 2010
SOURCE
CMAJ: Canadian Medical Association Journal;3/23/2010, Vol. 182 Issue 5, pE231
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on the Health Impact Fund proposed by Canadian economist Aidan Hollis that would reward the drug industry for the health impact of medicines with consideration on the selling cost. It says that the fund is a pay-for-performance alternation to the intellectual property rights system of the industry in which it also covers the giving of an option for the forgoing monopoly prices of new products. It explores how the fund works such the provision of alternatives to companies.
ACCESSION #
48913784

 

Related Articles

  • $Can2.8 billion rise in drug costs if EU's CETA passed.  // PharmacoEconomics & Outcomes News;2/19/2011, Issue 622, p8 

    The article focuses on a report commissioned by the Canadian Generic Pharmaceutical Association (CGPA) which warned of an annual increase of 2.8 billion Canadian dollars in the cost of drugs in Canada if the intellectual property clauses proposed by the European Union (EU) are included in the...

  • Do India's IP policies delay access to new drugs?  // PharmacoEconomics & Outcomes News;Sep2014, Vol. 712 Issue 1, p14 

    The article reports on the findings of researchers from the U.S. showing that the intellectual property (IP) policies in India that foster lower drug prices through generic competition, cost the country in delays to market of newly approved drugs and limit access to some drugs altogether.

  • Business barometer.  // Drug Topics;1/6/97, Vol. 141 Issue 1, p24 

    Presents charts reflecting the prices of drugs and overall financial performance of pharmaceutical services in the United States as of October 1996.

  • Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness? Vooren, Katelijne; Curto, Alessandro; Garattini, Livio // European Journal of Health Economics;May2015, Vol. 16 Issue 4, p341 

    The article offers information on therapies for hepatitis C in Europe. Topics discussed include pressure of worldwide economic crisis on national health care expenditures, debate on new drugs for hepatitis C in Europe that pose a major threat to pharmaceutical expenditure because of their high...

  • The Spirit of TRIPS and the Importation of Medicines Made under Compulsory License after the August 2003 TRIPS Council Agreement. Fayerman, Jessica J. // Northwestern Journal of International Law & Business;Fall2004, Vol. 25 Issue 1, p257 

    Focuses on the issue concerning the harmonization of pharmaceutical laws since the drafting of the Agreement on Trade-Related Aspects of Intellectual Property Rights in developing countries. Importance of the uniform world intellectual property laws for the promotion of free and balanced trade...

  • Is pharma moving to Africa? Aldridge, Susan // Pharmaceutical Technology Europe;Dec2007, Vol. 19 Issue 12, p15 

    The article reports on the plan of big pharmaceutical companies to build a pharmaceutical industry in Africa. It is discussed that the drugs for human immunodeficiency virus are driving pharmaceutical's involvement in the continent. It is noted that the difficulty in pricing, intellectual...

  • FROM TRIPS-PLUS TO RIGHTS-PLUS? EXPLORING RIGHT TO HEALTH IMPACT ASSESSMENT OF TRADE-RELATED INTELLECTUAL PROPERTY RIGHTS THROUGH THE THAI EXPERIENCE. Forman, Lisa // Asian Journal of WTO & International Health Law & Policy;Sep2012, Vol. 7 Issue 2, p347 

    Current international trade rules such as the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) may restrict domestic policy options to increase access to affordable medicines. This impact is amplified in bilateral and regional free trade agreements containing...

  • Patient access to rheumatoid arthritis treatments. Jönsson, Bengt // European Journal of Health Economics;Dec2007 Supplement 2, Vol. 8, p35 

    This paper is an introduction to the study “The Burden of Rheumatoid Arthritis and Patient Access to Treatment”. The objective of the study is to compare patient access to new drugs in Europe, North America and a selection of other countries, and to analyse the determinants of...

  • Pharmaceutical expenditure in the Czech Republic increased by 13% in 2005 to CZK64.6 billion.  // PharmacoEconomics & Outcomes News;4/8/2006, Issue 500, p29 

    Pharmaceutical expenditure in the Czech Republic increased by 13% in 2005 to CZK64.6 billion (Czech koruna), reports Scrip. The growth rate is at its highest since 1995, and compares with increases of up to 9% in the previous 4 years. A high proportion of spending was attributed to...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics